leisure time -WSS

leisure time

author：comprehensive 2025-09-30 19:25:23 - browse：84

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Biden's order seeks to regulate AI risk without stifling innovation

WSS

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

FDA has safety concerns on CRISPR

Changes to biosimilar regulatory framework must prioritize patients

Biotech lab space demand falls sharply

CDC advisers recommend seasonal use of Pfizer RSV shot

Lasker Awards 2023: Winners in biomedical research

hotspot

leisure time

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

STAT Virtual Event: Putting AI to the Test

Duchenne breakthrough therapy leaves behind pioneering families

CDC's new outbreak response network to include Northeastern

Wildfire smoke exposes gaps in outdoor worker protections

Maker of FluMist seeks to allow at

Hollywood unions extend contract negotiations for actors

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Jerome Adams on the need for new antivirals for Covid

Drug for rare kidney disease narrowly misses mark in clinical trial

hotspot

Cassava reveals details — and problems — with Alzheimer's study

Intarcia’s device

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Medtronic CEO on promising devices for diabetes, hypertension

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Second xenotransplant done with gene

focus

hotspot

focus

knowledge